Clinical trial
Donor Stem Cell Transplantation for Congenital Immunodeficiencies
NCT00426517 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00426517 |
|---|---|
| Title | Donor Stem Cell Transplantation for Congenital Immunodeficiencies |
| Official title | Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients With Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning With Campath- 1H or h-ATG, Radiation, and Sirolimus |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Inherited Immune Deficiencies |
| Intervention type | Drug |
| Interventions | Campath 1H, Busulfan, Horse Anti-human Thymocyte Globulin (h-ATG), Total Body Irradiation (TBI), Sirolimus or equivalent based on response |
| Enrollment | 48 |
| Start date | Jan 19, 2007 |
| Primary completion | Nov 1, 2019 |
| Completion | Nov 1, 2019 |
| First posted | Jan 24, 2007 |
| Last update posted | May 11, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: